JP2022523704A - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2022523704A JP2022523704A JP2021543509A JP2021543509A JP2022523704A JP 2022523704 A JP2022523704 A JP 2022523704A JP 2021543509 A JP2021543509 A JP 2021543509A JP 2021543509 A JP2021543509 A JP 2021543509A JP 2022523704 A JP2022523704 A JP 2022523704A
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- pharmaceutical composition
- acid
- composition according
- chain fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019073112 | 2019-01-25 | ||
| CNPCT/CN2019/073112 | 2019-01-25 | ||
| PCT/CN2020/073099 WO2020151633A1 (en) | 2019-01-25 | 2020-01-20 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523704A true JP2022523704A (ja) | 2022-04-26 |
| JP2022523704A5 JP2022523704A5 (cg-RX-API-DMAC7.html) | 2023-01-31 |
Family
ID=71736646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543509A Pending JP2022523704A (ja) | 2019-01-25 | 2020-01-20 | 医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220193095A9 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3914234A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022523704A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113473974A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020151633A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114026106B (zh) | 2019-03-06 | 2025-01-21 | 普洛拉治疗公司 | 阿比特龙前药 |
| CN114762693A (zh) * | 2020-12-31 | 2022-07-19 | 成都海博为药业有限公司 | 一种载药量高的阿比特龙药物组合物及其制备方法及用途 |
| CN117120034A (zh) | 2021-02-15 | 2023-11-24 | 普洛佩拉治疗公司 | 阿比特龙前药 |
| KR20230165280A (ko) * | 2021-04-01 | 2023-12-05 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 제약 제제에서 음이온 킬레이트화제로서의 인지질 |
| WO2023038933A1 (en) * | 2021-09-08 | 2023-03-16 | Propella Therapeutics, Inc. | Oral abiraterone formulations |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH024712A (ja) * | 1988-06-24 | 1990-01-09 | Eisai Co Ltd | ビタミンe又はその誘導体の吸収促進組成物 |
| WO2008044659A1 (en) * | 2006-10-06 | 2008-04-17 | Kaneka Corporation | Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| JP2013516433A (ja) * | 2009-12-31 | 2013-05-13 | ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ,エルエルシー | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
| JP2015515970A (ja) * | 2012-05-04 | 2015-06-04 | ヤゴテック アーゲー | アビラテロン酢酸エステルを含む薬学的組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030149061A1 (en) * | 2000-04-04 | 2003-08-07 | Yoshitaka Nishihara | Oily compositions containing highly fat-soluble drugs |
| CA2626579A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| US20130303495A1 (en) * | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
| GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| CN103169712B (zh) * | 2011-12-20 | 2017-10-27 | 重庆华邦制药有限公司 | 提高生物利用度的度他雄胺制剂及其制备方法 |
| KR20140043579A (ko) * | 2012-09-24 | 2014-04-10 | 한국콜마주식회사 | 무복계면 디클로페낙나트륨 및 그 제조방법 |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2016044701A1 (en) * | 2014-09-18 | 2016-03-24 | Iceutica Inc. | Abiraterone acetate formulation and methods of use |
| WO2017037647A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical compositions of abiraterone |
| CN105055314A (zh) * | 2015-09-28 | 2015-11-18 | 杭州安德科技有限公司 | 一种阿比特龙的口腔喷雾剂及其使用和制备方法 |
| CA2922959C (en) * | 2016-03-03 | 2018-01-02 | Pankaj Modi | Orally administrable composition |
-
2020
- 2020-01-20 JP JP2021543509A patent/JP2022523704A/ja active Pending
- 2020-01-20 WO PCT/CN2020/073099 patent/WO2020151633A1/en not_active Ceased
- 2020-01-20 EP EP20745571.8A patent/EP3914234A4/en not_active Withdrawn
- 2020-01-20 CN CN202080010385.3A patent/CN113473974A/zh active Pending
- 2020-03-11 US US16/815,569 patent/US20220193095A9/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH024712A (ja) * | 1988-06-24 | 1990-01-09 | Eisai Co Ltd | ビタミンe又はその誘導体の吸収促進組成物 |
| WO2008044659A1 (en) * | 2006-10-06 | 2008-04-17 | Kaneka Corporation | Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| JP2013516433A (ja) * | 2009-12-31 | 2013-05-13 | ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ,エルエルシー | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
| JP2015515970A (ja) * | 2012-05-04 | 2015-06-04 | ヤゴテック アーゲー | アビラテロン酢酸エステルを含む薬学的組成物 |
Non-Patent Citations (2)
| Title |
|---|
| INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 12, JPN6023043304, 2017, pages 4869 - 4878, ISSN: 0005324628 * |
| オレオサイエンス, vol. 18, no. 8, JPN6023043305, 2018, pages 29 - 35, ISSN: 0005324627 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3914234A1 (en) | 2021-12-01 |
| EP3914234A4 (en) | 2022-09-14 |
| US20200237784A1 (en) | 2020-07-30 |
| CN113473974A (zh) | 2021-10-01 |
| US20220193095A9 (en) | 2022-06-23 |
| WO2020151633A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7394974B2 (ja) | 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用 | |
| WO2020151633A1 (en) | Pharmaceutical compositions | |
| US10286077B2 (en) | Steroid hormone compositions in medium chain oils | |
| US20170281647A1 (en) | Steroid hormone compositions in medium chain oils | |
| JP2017516768A (ja) | 天然の併用ホルモン補充療法剤及び療法 | |
| WO2014009434A1 (en) | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate | |
| US11123351B2 (en) | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | |
| JP2022518356A (ja) | レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物 | |
| JP2022523704A5 (cg-RX-API-DMAC7.html) | ||
| CN114344309A (zh) | 一种别孕烷醇酮衍生物自乳化制剂及其制备方法 | |
| JP2009518443A (ja) | 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤 | |
| AU2018332191B2 (en) | Pharmaceutical composition | |
| KR102238478B1 (ko) | 구강 전달용 지방균형잡힌 장쇄 테스토스테론 에스테르 | |
| JP2019206540A (ja) | プロゲステロン製剤 | |
| TW202128150A (zh) | 3'—[(2z)—[1—(3,4—二甲基苯基)—1,5—二氫—3—甲基—5—側氧基—4h—吡唑—4—亞基]肼基]—2'—羥基—[1,1'—聯苯基]—3—甲酸及其鹽配製物 | |
| RU2779262C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА | |
| JP2003160496A (ja) | グリチルリチン経口投与剤 | |
| WO2022170398A1 (en) | Formulations for improved bioavailability of fenretinide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231020 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240515 |